What will pharma do now on health reform?

It's that old you-never-miss-it-till-it's-gone story: Now that the Democrats have lost Sen. Ted Kennedy's Senate seat to the Republicans, they must feel as if they squandered those good old days of a 60-40 majority. Now, healthcare reform advocates face several not-so-wonderful options for getting a bill passed.

Pushing the Senate version of the bill through the House unchanged, for instance; House Reps aren't crazy about that idea. Treating healthcare reform as a budget bill that would need only 51 votes in the Senate; some Senate Dems say they wouldn't go along. Throwing up their hands and walking away? A few Democrats already say they're giving up, making those good old supermajority days seem even better. Because if Democrats don't have anything to show for their first year with those numbers, then the midterm elections could be really ugly.

With healthcare reform up in the air, so is pharma's $80 billion--or is it $90 billion now?--cost-cutting with the White House. But so is the expansion of health insurance that was predicted to deliver growth to Big Pharma's revenues. What will the industry and its lobbyists do now? We'll have to wait and see.

- read the Bloomberg story
- get the piece in the Wall Street Journal
- see the New York Times' take

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.